Skip to main content

Table 3 Prevalence of most dispensed chronic medications in men (n = 351) and women (n = 1329) centenarians. Drugs are listed in descending order of total prevalence, and only those with prevalence equal to or greater than 1% are represented

From: Health of Spanish centenarians: a cross-sectional study based on electronic health records

ATCa code

Chronic medication

Men (%)

Women (%)

P value

A02B

Drugs for peptic ulcer and GERDb

53.9

50.2

n.s.c

B01A

Antithrombotic agents

43.6

39.9

n.s.

N02B

Other analgesics and antipyretics

34.1

36.4

n.s.

C03C

High-ceiling diuretics

31.5

34.9

n.s.

N05B

Anxiolytics

13.9

23.4

<0.001

N06A

Antidepressants

12.8

14.7

n.s.

N05C

Hypnotics and sedatives

9.9

14.7

<0.05

N05A

Antipsychotics

11.4

14.2

n.s.

C09A

ACEd inhibitors, plain

7.3

14.9

<0.001

B03A

Iron preparations

12.8

10.7

n.s.

C08C

Selective calcium channel blockers with mainly vascular effects

13.9

10.3

n.s.

C05C

Capillary stabilizing agents

4.4

11.4

<0.05

C01D

Vasodilators used in cardiac diseases

8.1

10.3

n.s.

C09C

Angiotensin II receptor blockers, plain

7.0

9.0

n.s.

M02A

Topical products for joint and muscular pain

6.1

9.0

n.s.

C09D

Angiotensin II receptor blockers, combinations

5.9

8.4

n.s.

S01E

Antiglaucoma preparations and miotics

7.7

7.3

n.s.

A06A

drugs for constipation

8.1

6.7

n.s.

M01A

Antiinflammatory and antirheumatic products, non-steroids

10.3

6.1

<0.05

C01A

Cardiac glycosides

8.1

6.6

n.s.

N06B

Psychostimulants, agents used for ADHDe and nootropics

8.8

6.0

n.s.

R05C

Expectorants, excl. Combinations with cough suppressants

8.4

5.5

n.s.

A10B

Blood glucose lowering drugs, excl. Insulins

5.1

5.9

n.s.

V06X

General nutrients

5.5

5.6

n.s.

B03B

Vitamin B12 and folic acid

5.1

5.5

n.s.

C07A

Beta blocking agents

4.4

5.7

n.s.

N02A

Opioids

2.2

6.2

<0.05

G04C

Drugs used in benign prostatic hypertrophy

26.0

0.0

<0.001

C10A

Lipid modifying agents, plain

6.6

4.3

n.s.

C04A

Peripheral vasodilators

5.5

4.1

n.s.

R03A

Adrenergics, inhalants

7.3

3.7

<0.05

R03B

Other drugs for obstructive airway diseases, inhalants

7.3

3.7

<0.05

S01X

Other ophthalmologicals

3.7

4.4

n.s.

C09B

ACE inhibitors, combinations

3.7

4.3

n.s.

D01A

Antifungals for topical use

4.0

4.2

n.s.

C03D

Potassium-sparing agents

5.9

3.6

n.s.

C03E

Diuretics and potassium-sparing agents in combination

1.1

4.6

<0.05

A03F

Propulsives

1.1

4.1

<0.05

R06A

Antihistamines for systemic use

5.5

3.1

n.s.

C01E

Other cardiac preparations

3.7

3.4

n.s.

C03B

Low-ceiling diuretics, excl. Thiazides

2.6

3.6

n.s.

C08D

Selective calcium channel blockers with direct cardiac effects

3.7

2.7

n.s.

A12A

Calcium

0.7

3.3

<0.05

A12B

Potassium

1.8

3.1

n.s.

D07A

Corticosteroids, plain

4.8

2.3

<0.05

M04A

Antigout preparations

5.9

2.0

<0.001

N03A

Antiepileptics

1.8

3.0

n.s.

N07C

Antivertigo preparations

2.9

2.6

n.s.

J01 M

Quinolone antibacterials

4.0

1.9

n.s.

H02A

Corticosteroids for systemic use, plain

3.7

1.7

n.s.

H03A

Thyroid preparations

1.1

2.3

n.s.

J01X

Other antibacterials

2.9

1.4

n.s.

J01C

Beta-lactam antibacterials, penicillins

2.6

1.4

n.s.

N06D

Anti-dementia drugs

1.8

1.6

n.s.

V06Z

General nutrients

2.9

1.4

n.s.

S01A

Antiinfectives

0.7

1.7

n.s.

A10A

Insulins and analogues

1.5

1.4

n.s.

C03A

Low-ceiling diuretics, thiazides

0.7

1.4

n.s.

J01D

Other beta-lactam antibacterials

1.1

1.4

n.s.

R05D

Cough suppressants, excl. Combinations with expectorants

2.3

1.0

n.s.

H03B

Antithyroid preparations

0.7

1.1

n.s.

  1. aAnatomical Therapeutic Chemical Classification System; bGastroesophageal reflux disease; cNot statistically significant; dAngiotensin-converting-enzyme; eAttention deficit hyperactivity disorder